U.S. federal workplace education reviewed September 22, 2026—not legal, labor, medical, union, or employment advice. The current 49 CFR Part 40 text, the employee's DOT agency rules, employer policy, collective-bargaining terms, and qualified counsel control a specific situation.
THE USEFUL PART
Keep these in your head.
- DOT-regulated safety-sensitive testing covers marijuana; DOT's CBD notice says CBD use is not a legitimate medical explanation for a confirmed marijuana-positive result.
- State legalization, a cannabis recommendation, a dispensary receipt, or a retail product label does not by itself excuse a DOT marijuana-positive test.
- A laboratory result, the Medical Review Officer process, removal from safety-sensitive duties, and the return-to-duty process are distinct steps with different decision-makers.
- Do not use internet detection clocks or detox tactics. Preserve notices, follow official deadlines, and use a qualified representative or attorney for individual rights and disputes.
First identify whether the job and test are actually DOT-regulated
DOT's employee materials describe safety-sensitive workers in aviation, commercial trucking, railroads, public transportation, pipelines, and maritime industries. A company in transportation can also run a separate non-DOT program. The collection site, form, policy, and notice should identify which authority applies; do not assume every employer test is “DOT” because the business has trucks, drivers, aircraft, vessels, or federal contracts.
Keep the DOT agency straight: FAA, FMCSA, FRA, FTA, PHMSA, and USCG have role-specific rules layered onto Part 40 procedures. The right starting page is the agency and program named on the official record.
Why a CBD package cannot clear the DOT gate
DOT's February 18, 2020 CBD notice states three points that remain central to its published policy: DOT requires testing for marijuana, not CBD; labeling of many CBD products may be misleading because products can contain more THC than stated; and CBD use is not a legitimate medical explanation for a laboratory-confirmed marijuana-positive result. DOT therefore cautions safety-sensitive employees about CBD use.
That notice is guidance and says it does not itself have the force and effect of law except as authorized by law or incorporated into a contract. The testing rules and modal-agency regulations remain the controlling authorities. The practical conclusion is narrower and firmer than a marketing claim: a “hemp,” “full spectrum,” “broad spectrum,” or “THC-free” package cannot guarantee a DOT outcome.
- A state-legal purchase does not change the federal DOT testing rule.
- A certificate of analysis describes a tested sample under stated limits; it cannot promise the content of every unit or another laboratory's result.
- A product refund or brand guarantee does not reverse an employer or federal process.
- A medical recommendation for cannabis is not the same as a federally recognized medical explanation under Part 40.
- Stopping shortly before a test does not create a reliable prediction for an individual specimen.
Keep the testing and employment steps separate
| Stage | What it does | What it does not decide by itself |
|---|---|---|
| Collection | Creates a documented specimen under the applicable procedure. | It is not the final laboratory or employment decision. |
| Initial test | Screens for the named drug classes under program rules. | A nonnegative screen is not the same as a verified positive. |
| Confirmatory test | Uses a separate analytical method and program cutoff for the identified analyte or metabolite. | It does not independently decide whether a medical explanation is accepted. |
| Medical Review Officer | Reviews the result and relevant medical information under Part 40. | The MRO does not rewrite DOT policy to accommodate retail CBD or state marijuana law. |
| Employer action | Removes a verified-positive employee from DOT safety-sensitive functions and applies governing rules and policy. | Removal is not the same question as every pay, leave, discipline, or termination right. |
| Return-to-duty | Requires the specified Substance Abuse Professional and testing process before resuming covered functions. | Finishing one step does not erase follow-up obligations. |
The site's broader drug-testing guide explains specimens, screening, confirmation, metabolites, and evidence limits. This page narrows the issue to federal DOT safety-sensitive work.
What to do when contacted about a result
- Verify the caller and case.
Use the official employer or MRO contact information on existing records, not an unexpected text link or a fee request.
- Respond within the stated deadline.
Write down the date, time, name, callback route, instructions, and documents requested. Silence can have procedural consequences.
- Provide complete, truthful information.
Disclose relevant prescriptions and medical information through the authorized channel. Do not alter a label, borrow a prescription, create a receipt, or coach another person.
- Ask about the split specimen and review rights.
Part 40 provides specific processes and time limits. Ask the MRO or qualified representative what applies now; do not rely on a generic online checklist.
- Do not perform safety-sensitive duties when prohibited.
Follow the official removal instruction. Do not drive, operate, dispatch, maintain, or otherwise perform a covered function in violation of a direction.
- Separate the legal questions.
The result process, disability or medical issues, collective-bargaining rights, leave/pay, discipline, privacy, and state-law protections may require different expertise.
Understand the return-to-duty sequence without shortcuts
DOT's employee page explains that after a DOT drug or alcohol violation, an employee cannot return to safety-sensitive duties until completing the return-to-duty process. That generally involves an evaluation by a DOT-qualified Substance Abuse Professional, following the education or treatment recommendation, a follow-up evaluation, an employer decision to proceed, a negative return-to-duty test, and a prescribed follow-up testing plan.
The Substance Abuse Professional is not the employee's advocate, the employer's advocate, or a provider who can guarantee reinstatement. Completing the process establishes eligibility for an employer to consider returning the person to covered work; it does not compel hiring or restoration of a particular position. Use the current official rules and directory instructions, and beware of businesses promising an instant certificate, a guaranteed result, or a way around observed testing.
Build a pre-use decision record before a crisis
This record does not make a product safe or create a defense. It prevents the most common category error: treating a retail label as if it were an official workplace determination. If maintaining a safety-sensitive qualification is essential, the most conservative response to uncertain THC exposure is to avoid the product and discuss the underlying need with a qualified clinician.
Official sources and scope
Sources reviewed September 22, 2026. DOT's CBD notice was issued February 18, 2020 and remains published; it identifies itself as guidance. Current 49 CFR Part 40 and the applicable DOT agency rule control. This page provides no individualized legal conclusion, detection window, detox method, or promise about employment.
Big Bud Man standard: know the source, read the batch, protect kids and pets, and never drive impaired.